Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas
NCT00390234Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2006
- Primary completion
- Sep 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in soft tissue sarcoma (STS), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate at 3 years and Progression-Free Survival at 6 months. Started Sep 2006; status: completed.
02
Drugs
aflibercept
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00390234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390234.